Long-term Effects of an Angiotensin II Type 1 Receptor Blocker in Hypertensive Patients with Chronic Kidney Disease and Metabolic Syndrome

Long-term Effects of an Angiotensin II Type 1 Receptor Blocker in Hypertensive Patients with Chronic Kidney Disease and Metabolic Syndrome - Long-term effects of ARB on hypertension with CKD and MetS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010892

Enrollment

160

Registered

2013-06-10

Start date

2004-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension Chronic kidney disease Metabolic syndrome

Interventions

Telmisartan Imidapril Amlodipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertension Metabolic syndrome Chronic Kidney Disease stage G3 or G4

Exclusion criteria

Exclusion criteria: heart failure or left ventricular dysfunction (ejection fraction <45%) history of ischemic heart disease such as angina pectoris or myocardial infarction arteriosclerosis obliterans (ankle-brachial index [ABI] <0.9) intake of antioxidants such as vitamins C and E or thiazolidinediones such as pioglitazone insulin therapy

Design outcomes

Primary

Measure	Time frame
Hospitalization or death due to heart failure, angina pectoris, myocardial infarction or stroke	—

Secondary

Measure	Time frame
Endothelial function, aortic stiffness, inflammation, oxidative stress, and insulin resistance	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026